메뉴 건너뛰기




Volumn 7, Issue 7, 2009, Pages 801-805

The CASTLE study: Atazanavir/r versus lopinavir/r in antiretroviral-naive patients

Author keywords

Antiretroviral therapy naive patients; Atazanavir ritonavir; Lopinavir ritonavir

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ANTIINFECTIVE AGENT; ANTIVIRUS AGENT; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; DARUNAVIR; DARUNAVIR PLUS RITONAVIR; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR; FOSAMPRENAVIR PLUS RITONAVIR; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; OMEPRAZOLE; TENOFOVIR; UNCLASSIFIED DRUG;

EID: 70350639443     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/ERI.09.66     Document Type: Review
Times cited : (3)

References (34)
  • 1
    • 33645277852 scopus 로고    scopus 로고
    • Comparisons of causes of death and mortality rates among HIV-infected persons: Analysis of the pre-, early, and late HAART (highly active antiretroviral therapy) eras
    • Crum NF, Riffenburgh RH, Wegner S et al. Comparisons of causes of death and mortality rates among HIV-infected persons: analysis of the pre-, early, and late HAART (highly active antiretroviral therapy) eras. J. Acquir. Immune Defic. Syndr. 41, 194-200 (2006).
    • (2006) J. Acquir. Immune Defic. Syndr. , vol.41 , pp. 194-200
    • Crum, N.F.1    Riffenburgh, R.H.2    Wegner, S.3
  • 3
    • 48949097660 scopus 로고    scopus 로고
    • Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel
    • Most recent International AIDS Society-USA guidelines for antiretroviral therapy
    • Hammer SM, Eron JJ Jr, Reiss P et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 300, 555-570 (2008). • Most recent International AIDS Society-USA guidelines for antiretroviral therapy.
    • (2008) JAMA , vol.300 , pp. 555-570
    • Hammer, S.M.1    Eron Jr., J.J.2    Reiss, P.3
  • 4
    • 34249691283 scopus 로고    scopus 로고
    • Protease inhibitor-based regimens for HIV therapy: Safety and efficacy
    • DOI 10.1097/QAI.0b013e3180600709, PII 0012633420070601100003
    • Walmsley S. Protease inhibitor-based regimens for HIV therapy: safety and efficacy. J. Acquir. Immune Defic. Syndr. 45 (Suppl. 1), S5-S13 (2007). (Pubitemid 46828214)
    • (2007) Journal of Acquired Immune Deficiency Syndromes , vol.45 , Issue.SUPPL. 1
    • Walmsley, S.1
  • 5
    • 34249711388 scopus 로고    scopus 로고
    • The role of adherence to antiretroviral therapy in the management of HIV infection
    • DOI 10.1097/QAI.0b013e3180600766, PII 0012633420070601100004
    • Conway B. The role of adherence to antiretroviral therapy in the management of HIV infection. J. Acquir. Immune Defic. Syndr. 45(Suppl. 1), S14-S18 (2007). (Pubitemid 46828215)
    • (2007) Journal of Acquired Immune Deficiency Syndromes , vol.45 , Issue.SUPPL. 1
    • Conway, B.1
  • 8
    • 33746706779 scopus 로고    scopus 로고
    • The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: A randomised non-inferiority trial
    • DOI 10.1016/S0140-6736(06)69155-1, PII S0140673606691551
    • Eron J Jr, Yeni P, Gathe J Jr et al. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial. Lancet 368, 476-482 (2006). • The KLEAN study was designed to compare the efficacy and safety of fosamprenavir-ritonavir and lopinavir-ritonavir in treatment-naive patients. (Pubitemid 44160731)
    • (2006) Lancet , vol.368 , Issue.9534 , pp. 476-482
    • Eron Jr., J.1    Yeni, P.2    Gathe Jr., J.3    Estrada, V.4    DeJesus, E.5    Staszewski, S.6    Lackey, P.7    Katlama, C.8    Young, B.9    Yau, L.10    Sutherland-Phillips, D.11    Wannamaker, P.12    Vavro, C.13    Patel, L.14    Yeo, J.15    Shaefer, M.16
  • 9
    • 49649092719 scopus 로고    scopus 로고
    • Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48
    • The ARTEMIS study was designed to compare the efficacy and safety of darunavir-ritonavir with lopinavir-ritonavir in treatment-naive patients
    • Ortiz R, DeJesus E, Khanlou H et al. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. AIDS 22, 1389-1397 (2008). • The ARTEMIS study was designed to compare the efficacy and safety of darunavir-ritonavir with lopinavir-ritonavir in treatment-naive patients.
    • (2008) AIDS , vol.22 , pp. 1389-1397
    • Ortiz, R.1    DeJesus, E.2    Khanlou, H.3
  • 10
    • 49649112490 scopus 로고    scopus 로고
    • Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study
    • Original CASTLE study, which details design and primary results. This study was designed to compare the efficacy, safety and tolerability of atazanavir-ritonavir and lopinavir-ritonavir in antiretroviral-naive patients
    • Molina JM, Andrade-Villanueva J, Echevarria J et al. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet 372, 646-655 (2008). •• Original CASTLE study, which details design and primary results. This study was designed to compare the efficacy, safety and tolerability of atazanavir-ritonavir and lopinavir-ritonavir in antiretroviral-naive patients.
    • (2008) Lancet , vol.372 , pp. 646-655
    • Molina, J.M.1    Andrade-Villanueva, J.2    Echevarria, J.3
  • 13
    • 11144357656 scopus 로고    scopus 로고
    • Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: A randomized open-label trial, the 2NN Study
    • van Leth F, Phanuphak P, Ruxrungtham K et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomized open-label trial, the 2NN Study. Lancet 363, 1253-1263 (2004).
    • (2004) Lancet , vol.363 , pp. 1253-1263
    • Van Leth, F.1    Phanuphak, P.2    Ruxrungtham, K.3
  • 15
    • 30944468562 scopus 로고    scopus 로고
    • Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV
    • Study 934 Group
    • Gallant JE, DeJesus E, Arribas JR et al.; Study 934 Group. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N. Engl. J. Med. 354, 251-260 (2006).
    • (2006) N. Engl. J. Med. , vol.354 , pp. 251-260
    • Gallant, J.E.1    DeJesus, E.2    Arribas, J.R.3
  • 16
    • 38649100026 scopus 로고    scopus 로고
    • Efficacy and safety of atazanavir, with or without ritonavir, as part of once-daily highly active antiretroviral therapy regimens in antiretroviral-naive patients
    • DOI 10.1097/QAI.0b013e31815ace6a
    • Malan DR, Krantz E, David N et al. Efficacy and safety of atazanavir, with or without ritonavir, as part of once-daily highly active antiretroviral therapy regimens in antiretroviral-naive patients. J. Acquir. Immune Defic. Syndr. 47, 161-167 (2008). (Pubitemid 351172182)
    • (2008) Journal of Acquired Immune Deficiency Syndromes , vol.47 , Issue.2 , pp. 161-167
    • Malan, D.R.1    Krantz, E.2    David, N.3    Wirtz, V.4    Hammond, J.5    McGrath, D.6
  • 17
    • 62649148454 scopus 로고    scopus 로고
    • Efficacy and safety of ritonavir-boosted and unboosted atazanavir among antiretroviral-naive patients
    • Horberg M, Klein D, Hurley L et al. Efficacy and safety of ritonavir-boosted and unboosted atazanavir among antiretroviral-naive patients. HIV Clin. Trial 9, 367-374 (2008).
    • (2008) HIV Clin. Trial , vol.9 , pp. 367-374
    • Horberg, M.1    Klein, D.2    Hurley, L.3
  • 18
    • 65649151755 scopus 로고    scopus 로고
    • Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy: Final 48-week clinical and virologic outcomes
    • Wilkin TJ, McKinnon JE, Dirienzo AG et al. Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy: final 48-week clinical and virologic outcomes. J. Infect. Dis. 199, 866-871 (2009).
    • (2009) J. Infect. Dis. , vol.199 , pp. 866-871
    • Wilkin, T.J.1    McKinnon, J.E.2    Dirienzo, A.G.3
  • 19
    • 33748116898 scopus 로고    scopus 로고
    • Mortality in the highly active antiretroviral therapy era: Changing causes of death and disease in the HIV outpatient study
    • Palella FJ Jr, Baker RK, Moorman AC et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J. Acquir. Immune Defic. Syndr. 43, 27-34 (2006).
    • (2006) J. Acquir. Immune Defic. Syndr. , vol.43 , pp. 27-34
    • Palella Jr., F.J.1    Baker, R.K.2    Moorman, A.C.3
  • 20
    • 34247537169 scopus 로고    scopus 로고
    • Class of antiretroviral drugs and the risk of myocardial infarction
    • The DAD Study Group
    • Friis-Møller N, Reiss P, Sabin C et al.; The DAD Study Group. Class of antiretroviral drugs and the risk of myocardial infarction. N. Engl. J. Med. 356, 1723-1735 (2007).
    • (2007) N. Engl. J. Med. , vol.356 , pp. 1723-1735
    • Friis-Møller, N.1    Reiss, P.2    Sabin, C.3
  • 22
    • 37549038211 scopus 로고    scopus 로고
    • Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: Final results of the SLOAT trial
    • Soriano V, Garcia-Gasco P, VIspo E et al. Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial. J. Antimicrob. Chemother. 61, 200-205 (2008).
    • (2008) J. Antimicrob. Chemother. , vol.61 , pp. 200-205
    • Soriano, V.1    Garcia-Gasco, P.2    Vispo, E.3
  • 25
    • 70350667931 scopus 로고    scopus 로고
    • Reasons for treatment success with initial ART: An analysis of 2635 participants in 64 randomized, controlled trials and 14 prospective cohorts
    • Presented at: Abstract 782
    • Carr A, Amin J. Reasons for treatment success with initial ART: an analysis of 2635 participants in 64 randomized, controlled trials and 14 prospective cohorts. Presented at: 15th Conference on Retrovirus and Opportunistic Infections. Boston, MA, USA, 3-6 February 2008 (Abstract 782).
    • 15th Conference on Retrovirus and Opportunistic Infections. Boston, MA, USA, 3-6 February 2008
    • Carr, A.1    Amin, J.2
  • 27
    • 33847721472 scopus 로고    scopus 로고
    • Prolonged QT interval and torsades de pointes associated with atazanavir therapy
    • Ly T, Ruiz ME. Prolonged QT interval and torsades de pointes associated with atazanavir therapy. Clin. Infect. Dis. 44, e67-e68 (2007).
    • (2007) Clin. Infect. Dis. , vol.44
    • Ly, T.1    Ruiz, M.E.2
  • 29
    • 46349105916 scopus 로고    scopus 로고
    • Durability and outcome of initial antiretroviral treatments received during 2000-2005 by patients in the Swiss HIV Cohort Study
    • Vo TT, Ledergerber B, Keiser O et al. Durability and outcome of initial antiretroviral treatments received during 2000-2005 by patients in the Swiss HIV Cohort Study. J. Infect. Dis. 197, 1685-1694 (2008).
    • (2008) J. Infect. Dis. , vol.197 , pp. 1685-1694
    • Vo, T.T.1    Ledergerber, B.2    Keiser, O.3
  • 31
    • 25144448034 scopus 로고    scopus 로고
    • Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir
    • DOI 10.2165/00003088-200544100-00003
    • Le Tiec C, Barrail A, Goujard C, Taburet AM. Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir. Clin. Pharmacokinet. 44, 1035-1050 (2005). (Pubitemid 41356390)
    • (2005) Clinical Pharmacokinetics , vol.44 , Issue.10 , pp. 1035-1050
    • Le Tiec, C.1    Barrail, A.2    Goujard, C.3    Taburet, A.-M.4
  • 34
    • 67649538485 scopus 로고    scopus 로고
    • Panel on Antiretroviral Guidelines for Adults and Adolescents Department of Health and Human Services. 3 November Most recent Department of Health and Human Services guidelines for antiretroviral treatment
    • Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. 3 November 2008 www.aidsinfo.nih.gov/ ContentFiles/AdultandAdolescentGL.pdf. • Most recent Department of Health and Human Services guidelines for antiretroviral treatment.
    • (2008) Guidelines for the Use of Antiretroviral Agents in HIV-1-infected Adults and Adolescents


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.